Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States a…
$120.97-0.60%
报价 2026-11-13
市值
$24.66B
EV
$14.97B
PE (TTM)
13.9x
预期 PE (FY2026)
38.7x
52 周区间距高点 -6.9%
$90.30$129.93
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| INCYIncyte Corporation | $24.66B | -0.6% | +21.4% | 91.8% | 13.9x | 8.5x | 36.0x | |
| WATWaters Corporation | $45.24B | -0.4% | +105.3% | 58.9% | 28.0x | 18.3x | 155.1x | 高增长 |
| BIIBBiogen Inc. | $37.46B | +1.2% | +7.9% | 70.5% | 20.8x | 10.0x | 16.0x | |
| GMABGenmab A/S | $31.67B | -0.7% | – | 39.9% | 45.6x | 28.5x | 41.3x | |
| ILMNIllumina, Inc. | $31.3B | -1.2% | +7.6% | 66.4% | 49.5x | 30.8x | 43.1x | |
| RPRXRoyalty Pharma plc | $30.86B | +0.8% | +17.6% | 100% | 25.6x | 17.1x | 10.4x | |
| WSTWest Pharmaceutical Services, Inc. | $29.01B | +1.2% | +11.6% | 39.7% | 45.5x | 29.2x | 62.7x | |
| DGXQuest Diagnostics Incorporated | $28.56B | -0.0% | +10.0% | 33.7% | 24.3x | 15.6x | 21.0x | GARP |
| UTHRUnited Therapeutics Corporation | $25.18B | -0.4% | +1.6% | 86.1% | 17.9x | 12.8x | 21.0x | |
| 同行中位数 | – | – | +10.0% | 62.7% | 26.8x | 17.7x | 31.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。